GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » Shares Outstanding (Basic Average)

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Shares Outstanding (Basic Average) : 62.64 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. MoonLake Immunotherapeutics's average basic shares outstanding for the quarter that ended in Mar. 2024 was 62.64 Mil.


MoonLake Immunotherapeutics Shares Outstanding (Basic Average) Historical Data

The historical data trend for MoonLake Immunotherapeutics's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MoonLake Immunotherapeutics Shares Outstanding (Basic Average) Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23
Shares Outstanding (Basic Average)
- 29.36 49.12

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.06 43.72 53.52 60.03 62.64

MoonLake Immunotherapeutics Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


MoonLake Immunotherapeutics  (NAS:MLTX) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


MoonLake Immunotherapeutics Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of MoonLake Immunotherapeutics's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Executives
Matthias Bodenstedt officer: Chief Financial Officer DORFSTRASSE 29, ZUG V8 6300
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge director DORFSTRASSE 29, ZUG V8 6300
Kristian Reich officer: Chief Scientific Officer DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge director, officer: Chief Executive Officer DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il director, 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips director C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier director DORFSTRASSE 29, ZUG V8 6300
Spike Loy director DORFSTRASSE 29, ZUG V8 6300
Kara Lassen director DORFSTRASSE 29, ZUG V8 6300

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Headlines

From GuruFocus